Foluso Agboola discusses the Institute for Clinical and Economic Review's newest analysis, which has found that most new drugs approved over a three-year period were priced above value benchmarks, potentially costing the healthcare system $1.5 billion.
Gazyva is the first and only anti-CD20 monoclonal antibody approved to treat kidney inflammation associated with lupus.
The new model offers direct manufacturer pricing for weight loss drugs and a way to contribute to employee costs.
A new California law prohibits spread pricing and requires all rebates to be passed to health plans and is an important step toward transparency across the entire pharmacy supply chain, said Blue Shield of California’s Kathy Chang in an interview.
The world’s first fixed triple therapy formula is already approved in more than 50 countries outside the United States.
Repatha is now available for a monthly cash price of $239, through AmgenNow and GoodRx.
Novartis said that it is exploring an additional direct-to-employer model to increase access and affordability for cash-paying patients in the United States.
If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 diabetes.
Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year old.
AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery at a cash price that is up to 70% off the list price.
Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more than 1 million Americans.
MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.
Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer program that began earlier this month.
FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.
The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA.
Judi Health redefines health benefit management with a $400 million funding boost, enhancing transparency and efficiency for employers and health plans.
The complete response letter was issued by the FDA during a routine inspection of a third-party fill-finish facility, not because of an issue with apitegromab.
Brian K. Lee, Ph.D., of Drexel University Dornsife School of Public Health, says that despite the fact that some studies suggest there is link between acetaminophen use during pregnancy and neurodevelopmental disorders, there is a lack of evidence to support that conclusion.
Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy.
Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s disease.
Optum Rx has increased brand drug reimbursement minimums for 2,300 independent pharmacies that are not its network.
This spray formulation of bumetanide demonstrated a 33% faster absorption rate than oral bumetanide, according to clinical trial data.
Providers also have concerns about being able to stock certain medications, which would have a negative impact on their patients, according the Avalere Health survey.
Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher risks of liver transplant and death among treated patients.
Two separate analyses in Health Affairs find the One Big Beautiful Bill creates a loophole that exempts or delays orphan drugs — many of them blockbuster drugs that generate billions of dollars in sales — from price negotiations.
ICER’s comparative effectiveness and value review of Wegovy, Zepbound and oral semaglutide finds they are highly effective treatments with significant health benefits, but affordability and long-term management are still unresolved.
Leqembi IQLIK, a subcutaneous version of Leqembi, will launch on Oct. 6, 2025, with a list price of $375 per autoinjector.
Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight.
In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with nutrition and lifestyle support, as well as prescriptions for medications.
Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of 2025, with diabetes submissions to follow in 2026.
